186900-67-4 Usage
Uses
Used in Organic Synthesis:
(R)-3-cyclohexyl-2-methylpropanoic acid is used as a building block in organic synthesis for constructing more complex molecules due to its unique structural features, including a cyclohexyl ring and a methyl group.
Used in Pharmaceutical Research:
(R)-3-cyclohexyl-2-methylpropanoic acid is used as a key component in pharmaceutical research for developing new drugs, taking advantage of its ability to form various complex molecular structures that can interact with biological targets.
Used in the Treatment of Neurodegenerative Diseases:
In the medical field, (R)-3-cyclohexyl-2-methylpropanoic acid is used as a potential therapeutic agent for the treatment of certain neurodegenerative diseases, given its demonstrated potential in relevant studies.
If there are additional applications in different industries, they can be listed as follows:
Used in Chemical Industry:
(R)-3-cyclohexyl-2-methylpropanoic acid is used as an intermediate in the chemical industry for the production of various specialty chemicals, leveraging its reactive functional groups and structural diversity.
Used in Material Science:
(R)-3-cyclohexyl-2-methylpropanoic acid may be used as a component in the development of new materials, such as polymers or coatings, due to its potential to influence material properties through its unique molecular structure.
Check Digit Verification of cas no
The CAS Registry Mumber 186900-67-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,6,9,0 and 0 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 186900-67:
(8*1)+(7*8)+(6*6)+(5*9)+(4*0)+(3*0)+(2*6)+(1*7)=164
164 % 10 = 4
So 186900-67-4 is a valid CAS Registry Number.
186900-67-4Relevant academic research and scientific papers
PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)
-
, (2020/07/04)
Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those compounds for use in methods of treating muscular atrophy.
4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)
-
, (2019/08/26)
Inhibitors of ubiquitin specific protease 19 (USP19) of Formula (I) are provided, together with pharmaceutical compositions comprising said inhibitors, and methods of use thereof. The compounds can be used in in the treatment of muscular atrophy, obesity, insulin resistance or type II diabetes or in reducing the loss of muscle mass.
PHARMACEUTICAL COMPOUNDS
-
, (2018/02/28)
The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
Herpes ribonucleotide reductase inhibitors
-
, (2008/06/13)
Disclosed herein are compounds of the formula STR1 wherein R1 is hydrogen or (1-4C) alkyl, R2 is (1-4C) alkyl or a therapeutically acceptable salt thereof. The compounds are useful for treating herpes infections.
